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Introduction {#os12556-sec-0005}
============

The metabolism of bone cells is strongly regulated by estrogens and, therefore, postmenopausal osteoporosis is the most typical form of osteoporosis, which is characterized by low bone mass and microstructure damage of the bone tissue, leading to increased bone fragility and the risk of fracture[1](#os12556-bib-0001){ref-type="ref"}. Osteoporosis causes huge economic losses worldwide. Approximately 10 million men and women in the USA have osteoporosis[2](#os12556-bib-0002){ref-type="ref"}, 75 million people in Europe, North America and Japan are affected by it[3](#os12556-bib-0003){ref-type="ref"}, while the prevalence of osteoporosis in central south Chinese postmenopausal women is approximately 39.4%[4](#os12556-bib-0004){ref-type="ref"}.

Although the role of estrogen on bone metabolism has been documented, the mechanism of postmenopausal osteoporosis remains unclear and diagnostic strategies for postmenopausal osteoporosis are lacking.

Over the past century, many types of histone post‐translational modifications (PTM) have been identified, including lysine acetylation, arginine and lysine methylation, phosphorylation, proline isomerization, ubiquitination (Ub), ADP ribosylation, arginine citrullination, SUMOylation, carbonylation, and biotinylation[5](#os12556-bib-0005){ref-type="ref"}, [6](#os12556-bib-0006){ref-type="ref"}. It is known that the bone remodeling cycle is a balanced process that depends on the interaction, differentiation, and functions of the mesenchymal osteoblastic lineage and the hematopoietic osteoplastic lineage to maintain homeostasis of bone mass. Many histone post‐translational modifications are involved in bone remodeling cycle regulation.

Works such as Hein *et al*.[7](#os12556-bib-0007){ref-type="ref"} and Li *et al*.[8](#os12556-bib-0008){ref-type="ref"} have established that advanced glycation end products (AGE) could biphasically modulate bone resorption in osteoclast‐like cells and modify proteins in osteoporotic bone. A phosphoproteome of Milani *et al*.[9](#os12556-bib-0009){ref-type="ref"} revealed that phosphorylation is extremely important during osteoblast adhesion. In addition, a phosphoproteome study by Marumoto *et al*.[10](#os12556-bib-0010){ref-type="ref"} further reveals that hedgehog signaling has a critical role in osteoblast morphological transitions. However, the review of Bradley *et al*.[11](#os12556-bib-0011){ref-type="ref"} demonstrates that histone deacetylases have emerged as crucial regulators of both intramembranous and endochondral bone formation.

In summary, their results indirectly demonstrate the feasibility of revealing the mechanism of bone remodeling through the histone post‐translational modifications. The research of Zhang *et al*.[12](#os12556-bib-0012){ref-type="ref"} provides further relevant evidence. Zhang *et al*. examined the dynamics of distinct histone modifications during osteogenesis, including the dynamics of: H3K9/K14 and H4K12 acetylation; H3K4 mono‐, di‐ and tri‐methylation; H3K9 di‐methylation and H3K27 tri‐methylation in osteogenic genes, runt‐related transcription factor 2 (Runx2), osterix (Osx), alkaline phosphatase, and bone sialoprotein and osteocalcin during C3H10T1/2 osteogenesis.

However, the most important post‐translational modifications are ubiquitin modifications in bone metabolism. The ubiquitin‐proteasome system is one of the major quality control pathways responsible for cellular homeostasis[13](#os12556-bib-0013){ref-type="ref"}, [14](#os12556-bib-0014){ref-type="ref"}, [15](#os12556-bib-0015){ref-type="ref"}.

Ubiquitination is a posttranslational modification of proteins that controls almost every cellular metabolic pathway through a variety of combinations of linkages, either as a single moiety or as polymers[16](#os12556-bib-0016){ref-type="ref"}. These cellular metabolic pathways include, but are not limited to, transcription, cell signaling[17](#os12556-bib-0017){ref-type="ref"}, endocytic trafficking, DNA damage and repair[18](#os12556-bib-0018){ref-type="ref"}, and cell‐cycle control[19](#os12556-bib-0019){ref-type="ref"}. The ubiquitin system in humans consists of 2 E1, 35 E2, more than 600 E3 ubiquitin ligases, and hundreds of deubiquitylases[20](#os12556-bib-0020){ref-type="ref"}.

For more than a decade, investigators have shown that ubiquitin‐proteasome‐mediated protein degradation is critical in regulating the balance between bone formation and bone resorption[21](#os12556-bib-0021){ref-type="ref"}.

In addition, several studies have found that many ubiquitinases play an important role in bone metabolism, such as poly‐ubiquitination‐mediated RUNX2 degradation, which is an important cause of bone loss[22](#os12556-bib-0022){ref-type="ref"}, [23](#os12556-bib-0023){ref-type="ref"}. Surveys such as that conducted by Zhou *et al*.[24](#os12556-bib-0024){ref-type="ref"} have shown that RNF185 negatively regulates osteogenesis through the degradation of Dvl2 and the downregulation of the canonical Wnt signaling pathway. Many studies indicate that the muscle‐specific RING‐finger1 (MuRF1), a muscle‐specific ubiquitin ligas, is involved in osteoblastic bone formation and osteoclastic bone resorption[25](#os12556-bib-0025){ref-type="ref"}, [26](#os12556-bib-0026){ref-type="ref"}, [27](#os12556-bib-0027){ref-type="ref"}. Xu *et al*. [28](#os12556-bib-0028){ref-type="ref"} established that SMURF2 is an important regulator of the critical communication between osteoblasts and osteoclasts; the bone mass phenotype in Smurf2‐deficient and Smurf1‐deficient mice is opposite, indicating that SMURF2 has a non‐overlapping and opposite function to SMURF1. Jin *et al*.[29](#os12556-bib-0029){ref-type="ref"} found that Bre promoted the Mdm2‐mediated p53 ubiquitination and degradation by physically interacting with p53, and that Bre has a novel function in osteoblast differentiation through modulating the stability of p53.

In contrast, quantitative analysis of ubiquitylomes has proven to be a valuable tool for elucidating targets and mechanisms of the ubiquitin signaling systems[13](#os12556-bib-0013){ref-type="ref"}, [14](#os12556-bib-0014){ref-type="ref"}, [15](#os12556-bib-0015){ref-type="ref"}, as well as gaining insights into many diseases[30](#os12556-bib-0030){ref-type="ref"}, such as neuroblastoma[31](#os12556-bib-0031){ref-type="ref"}, cancer[32](#os12556-bib-0032){ref-type="ref"}, and Alzheimer\'s disease[33](#os12556-bib-0033){ref-type="ref"}.

To date, although the importance of ubiquitin modifications in bone metabolism has been reported, few studies have investigated ubiquitylomes in postmenopausal osteoporosis.

Here, we used ubiquitylomes analysis of the whole blood of postmenopausal women and postmenopausal osteoporosis patients, to discover the mechanism of ubiquitination in postmenopausal osteoporosis and investigate the ubiquitinated spectrum of novel targets between healthy postmenopausal women and postmenopausal osteoporosis patients. This expanded our understanding of the spectrum of novel targets that are differentially ubiquitinated in whole blood from healthy postmenopausal women and postmenopausal osteoporosis patients. Overall, the study highlights the utility of liquid chromatography coupled to tandem mass spectrometry (LC‐MS/MS) in performing comprehensive mapping of the human blood ubiquitylome changes in postmenopausal osteoporosis, which provides insight into underlying proteostasis pathways and targets that may have potential as novel diagnostic biomarkers in blood.

Materials and Methods {#os12556-sec-0006}
=====================

*Human Subjects* {#os12556-sec-0007}
----------------

This study included seven consecutive, unrelated, late postmenopausal women with osteoporosis and seven healthy postmenopausal women who visited the Second Affiliated Hospital of Zhejiang Chinese Medicine University. All subjects were Chinese Han females. Postmenopausal status was defined as no menses for at least 1 year after their last menses. Bone mineral density (BMD) of the lumbar spine (L~1~--L~4~) and femoral neck was measured by dual‐energy X‐ray absorptiometry using a QDR‐4500w instrument (Hologic, USA) at the Second Affiliated Hospital of Zhejiang Chinese Medicine University. The average age of the osteoporosis patients was 66.1 ± 3.4 years, with a range of 54--81 years. Seven age‐matched postmenopausal healthy volunteers (average age 68.9 ± 2.5 years, with a range of 58--79 years) were also recruited in Hangzhou.

*Diagnostic Criteria* {#os12556-sec-0008}
---------------------

The diagnosis of osteoporosis was based on the criteria recommended by the World Health Organization[34](#os12556-bib-0034){ref-type="ref"}, which included that the bone density (g/cm^2^) of the lumbar vertebra normal position and femoral neck was surveyed using dual‐energy X‐ray absorptiometry, compared with a normal adult of the same gender and race; T ≤ −2.5 could be diagnosed as osteoporosis, where T = (the standard deviation of measured value − peak bone mass)/normal adult bone density.

*Inclusion Criteria* {#os12556-sec-0009}
--------------------

Patients were included in the study based on the following criteria: (i) they conformed to the osteoporosis diagnostic criteria; (ii) they were postmenopausal women; and (iii) they were between 50 and 89 years old.

*Exclusion Criteria* {#os12556-sec-0010}
--------------------

Patients were excluded from the study based on the following criteria, which are derived from a previous study[35](#os12556-bib-0035){ref-type="ref"}: (i) all individuals with disorders known to cause abnormalities in the metabolism of bone or calcium, such as diabetes, Cushing\'s syndrome, functional change of the thyroid or parathyroid, osteomalacia, rheumatoid arthritis, multiple myeloma, bone tumor, osteoarthrosis, Paget\'s disease, and osteogenesis imperfecta; (ii) the individuals that also had severe primary cardiac diseases, or diseases of the cerebral vessels or hematopoietic system; (iii) the individuals that also had severe liver function or renal insufficiencies; (iv) the individuals who had taken drugs within the past 6 months that affect bone metabolism, such as estrogen, steroid hormones, calcitonin, parathyroid hormones, bisphosphonates, fluoride, vitamin D, anticonvulsant drugs, and diuretics; (v) the individuals who had a medical history of mental illness; and (vi) the individuals who had Alzheimer\'s disease.

*Ethical Review* {#os12556-sec-0011}
----------------

The study protocol was approved by the local Ethics Committee of the Second Affiliated Hospital of Zhejiang Chinese Medicine University and informed consent was obtained from all subjects.

*Trypsin Enzymatic Hydrolysis* {#os12556-sec-0012}
------------------------------

We added 8 mol urea to the sample to adjust the volume, then added dithiothreitol to a final concentration of 5 mmol, reducing at 56 °C for 30 min. Iodoacetamide was then added to a final concentration of 11 mmol and incubated for 15 min at room temperature in the dark. Finally, the urea concentration of the sample was diluted to less than 2 mol. Trypsin was added at a mass ratio of 1:50 (pancreatin: protein) and digested overnight at 37 °C. Trypsin was added at a mass ratio of 1:100 (pancreatin: protein) and continued to digest for 4 h.

*High‐Performance Liquid Chromatography Fractionation* {#os12556-sec-0013}
------------------------------------------------------

The peptides were fractionated by high pH reverse phase high‐performance liquid chromatography and the column was Agilent 300 Extend C18 (5 μm particle size, 4.6 mm id, 250 mm long). Finally, the fractional gradient of the peptide was 8%--32% acetonitrile, pH 6.0, allowing 60 min time to separate 60 components, and then the peptides were combined into four components, and the combined components were vacuum freeze‐dried for subsequent operations.

*Affinity Enrichment* {#os12556-sec-0014}
---------------------

The peptide was dissolved in IP buffer solution (100 mmol NaCl, 1 mmol EDTA, 50 mmol Tris‐HCl, 0.5% NP‐40, pH 8.0), and the supernatant was transferred to the pre‐washed ubiquitinated resin (resin number) PTM‐1104, from Hangzhou Jingjie Biotechnology, PTM Bio, placed on a rotary shaker at 4°C, gently shaken, and incubated overnight. Then, the resin was washed four times with IP buffer solution and twice with deionized water. Finally, the resin‐bound peptide was 0.1% trifluoroacetic acid eluate, eluted three times in total, and the eluate was collected and vacuum‐dried and drained. The salt was removed according to the C18 ZipTips instructions, vacuum‐dried, and drained for liquid‐mass spectrometry analysis.

*LC‐MS/MS Analysis* {#os12556-sec-0015}
-------------------

The tryptic peptides were dissolved in phase A in an aqueous solution of 0.1% formic acid and 2% acetonitrile; buffer B was an aqueous solution of 0.1% formic acid and 90% acetonitrile. Liquid phase gradient setting: 0--26 min, 5%--22% B; 26--34 min, 22%--35% B; 34--37 min, 35%--80% B; 37--40 min, 80% B, flow rate maintenance at 350 nL/min. The peptides were separated using an ultra‐high‐performance liquid phase system and injected into the NSI ion source for ionization, and then analyzed by Orbitrap FusionTM (Thermo) mass spectrometry. The ion source voltage was 2.0 kV, and the peptide precursor and its secondary fragments were detected and analyzed by high‐resolution Orbitrap. The primary mass spectrometer scan range was 350--1550 m/z and the scan resolution was set to 60 000; the secondary mass spectrometry scan range was 100 m/z and the Orbitrap scan resolution was 15 000. After the first‐stage scanning, the first 20 peptides with the highest signals were selected to enter the HCD collision cell and 35% of the fragmentation energy was used for secondary mass spectrometry. Finally, the automatic gain control (AGC) was set to 5E4, the signal threshold to 5000 ions/s, the maximum injection time to 200 ms, and the dynamic exclusion time of the tandem mass spectrometry to 15 s to avoid the parent ion. Then the scan was repeated.

*Database Search* {#os12556-sec-0016}
-----------------

Secondary mass spectral data was retrieved using Maxquant (v1.5.2.8). Search parameter settings: The database used was SwissProthuman (20 203 sequences), the anti‐library was added to calculate the false positive rate (FDR) caused by random matching, and a common pollution database was added to the database to eliminate the effect of contaminated proteins on the results. The enzyme digestion mode was Trypsin/P; the number of missed sites was 2; the minimum length of the peptide was seven amino acid residues; the maximum number of peptides was five; First search range was set to 5 ppm for precursor ions. Main search range set to 5 ppm and 0.02 Da for fragment ions. The mass error tolerance was 20 and 5 ppm. Finally, the fixed modification was cysteine alkylation, Author: the variable modification was methionine oxidation, protein N‐terminal acetylation, and lysine ubiquitination. The FDR for protein identification and PSM identification was 1%.

*Bioinformatics Analysis* {#os12556-sec-0017}
-------------------------

The Gene Ontology (GO) annotation proteome was derived from the UniProt‐GOA database (<http://www.ebi.ac.uk/GOA/>) and the InterProScan software[36](#os12556-bib-0036){ref-type="ref"}, [37](#os12556-bib-0037){ref-type="ref"}. First, identified protein ID was converted to UniProt ID and then mapped to GO IDs by protein ID. If some identified proteins were not annotated by the UniProt‐GOA database, the InterPro Scan software would be used to annotate proteins' GO functional classification based on the protein sequence alignment method. Finally, proteins are classified by GO annotation based on three categories: biological process, cellular component, and molecular function.

We used the Kyoto Encyclopedia of Genes and Genomes (KEGG) database for protein pathway analysis[38](#os12556-bib-0038){ref-type="ref"}. First, we used the KEGG online service tool KAAS to annotate proteins' KEGG database description. Then, we mapped the annotation result on the KEGG pathway database using the KEGG online service tool KEGG mapper. The protein complex analysis was conducted using the CORUM protein complex database. We used the InterPro domain database for protein domain annotation and Motif‐x for protein analysis.

Results {#os12556-sec-0018}
=======

*Overview of Global Ubiquitylome upon Postmenopausal Osteoporosis* {#os12556-sec-0019}
------------------------------------------------------------------

Altogether, 133 ubiquitinated sites and 102 proteins were quantified. The analysis of ubiquitylomes the whole blood in seven healthy postmenopausal women and seven postmenopausal osteoporosis patients revealed that 32 ubiquitinated sites on 25 proteins were upregulated and 101 ubiquitinated sites on 77 proteins were downregulated. The difference is more than 1.2 times as significant upregulation and less than 0.83 as a significant downregulation (*P* \< 0.05, Table [1](#os12556-tbl-0001){ref-type="table"}). Here, there are multiple ubiquitination sites on the same protein, some of which are rising and some are different.

###### 

The differentially expressed ubiquitinated sites and proteins in ubiquitylome of postmenopausal osteoporosis patients and healthy postmenopausal women

  Protein accession   Ratio    Regulated type   Protein description                                                                 Gene name   Score
  ------------------- -------- ---------------- ----------------------------------------------------------------------------------- ----------- --------
  P02656              0.212    Down             Apolipoprotein C‐III                                                                APOC3       161.24
  O43765              0.564    Down             Small glutamine‐rich tetratricopeptide repeat‐containing protein alpha              SGTA        131.66
  P00918              0.608    Down             Carbonic anhydrase 2                                                                CA2         125.73
  Q04323              0.26     Down             UBX domain‐containing protein 1                                                     UBXN1       88.708
  Q9P107              13.569   Up               GEM‐interacting protein                                                             GMIP        50.314
  P02675              0.373    Down             Fibrinogen beta chain                                                               FGB         117.84
  P02675              0.192    Down             Fibrinogen beta chain                                                               FGB         132.81
  P00736              0.115    Down             Complement C1r subcomponent                                                         C1R         70.165
  P21980              0.595    Down             Protein‐glutamine gamma‐glutamyltransferase 2                                       TGM2        102.53
  Q9BQE3              0.276    Down             Tubulin alpha‐1C chain                                                              TUBA1C      137.18
  Q9BQE3              0.546    Down             Tubulin alpha‐1C chain                                                              TUBA1C      115.54
  Q9BQE3              0.611    Down             Tubulin alpha‐1C chain                                                              TUBA1C      70.783
  Q9BQE3              0.416    Down             Tubulin alpha‐1C chain                                                              TUBA1C      95.618
  Q9BQE3              0.122    Down             Tubulin alpha‐1C chain                                                              TUBA1C      119.39
  P10599              0.336    Down             Thioredoxin                                                                         TXN         92.19
  P02774              0.121    Down             Vitamin D‐binding protein                                                           GC          50.786
  P15153              0.09     Down             Ras‐related C3 botulinum toxin substrate 2                                          RAC2        50.108
  P02647              0.483    Down             Apolipoprotein A‐I                                                                  APOA1       247.38
  P28066              0.23     Down             Proteasome subunit alpha type‐5                                                     PSMA5       161.68
  P32119              26.6     Up               Peroxiredoxin‐2                                                                     PRDX2       92.039
  P32119              0.696    Down             Peroxiredoxin‐2                                                                     PRDX2       145.46
  Q13228              5.732    Up               Selenium‐binding protein 1                                                          SELENBP1    141.07
  P63104              0.564    Down             14‐3‐3 protein zeta/delta                                                           YWHAZ       199.8
  P16157              0.589    Down             Ankyrin‐1                                                                           ANK1        150.11
  P16157              0.525    Down             Ankyrin‐1                                                                           ANK1        220.63
  P16157              0.184    Down             Ankyrin‐1                                                                           ANK1        154.72
  P16157              0.384    Down             Ankyrin‐1                                                                           ANK1        271.08
  P16157              2.199    Up               Ankyrin‐1                                                                           ANK1        122.28
  P16157              1.482    Up               Ankyrin‐1                                                                           ANK1        239.87
  P02649              0.183    Down             Apolipoprotein E                                                                    APOE        160.18
  Q14687              0.598    Down             Genetic suppressor element 1                                                        GSE1        116.54
  P20618              0.416    Down             Proteasome subunit beta type‐1                                                      PSMB1       132.13
  P02671              0.805    Down             Fibrinogen alpha chain                                                              FGA         81.017
  P02671              0.554    Down             Fibrinogen alpha chain                                                              FGA         71.153
  P04040              2.279    Up               Catalase                                                                            CAT         109.83
  P00441              0.442    Down             Superoxide dismutase \[Cu‐Zn\]                                                      SOD1        80.96
  Q9C0C9              1.597    Up               (E3‐independent) E2 ubiquitin‐conjugating enzyme                                    UBE2O       112.26
  Q9C0C9              4.967    Up               (E3‐independent) E2 ubiquitin‐conjugating enzyme                                    UBE2O       68.536
  Q9C0C9              0.581    Down             (E3‐independent) E2 ubiquitin‐conjugating enzyme                                    UBE2O       97.597
  Q9C0C9              4.099    Up               (E3‐independent) E2 ubiquitin‐conjugating enzyme                                    UBE2O       88.021
  Q9C0C9              0.809    Down             (E3‐independent) E2 ubiquitin‐conjugating enzyme                                    UBE2O       124.21
  P62258              0.227    Down             14--3‐3 protein epsilon                                                             YWHAE       76.847
  P25789              0.473    Down             Proteasome subunit alpha type‐4                                                     PSMA4       105.2
  P25789              0.349    Down             Proteasome subunit alpha type‐4                                                     PSMA4       127.56
  P27348              0.36     Down             14‐3‐3 protein theta                                                                YWHAQ       120.46
  P22314              95.567   Up               Ubiquitin‐like modifier‐activating enzyme 1                                         UBA1        168.62
  P22314              0.166    Down             Ubiquitin‐like modifier‐activating enzyme 1                                         UBA1        118.32
  P28070              0.489    Down             Proteasome subunit beta type‐4                                                      PSMB4       205.62
  P23634              0.405    Down             Plasma membrane calcium‐transporting ATPase 4                                       ATP2B4      85.355
  P0C0L4              0.43     Down             Complement C4‐A                                                                     C4A         109.71
  P62158              12.941   Up               Calmodulin                                                                          CALM1       62.099
  P30153              1.362    Up               Serine/threonine‐protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform   PPP2R1A     120.03
  Q96BN8              0.071    Down             Ubiquitin thioesterase otulin                                                       OTULIN      109.07
  P11171              0.457    Down             Protein 4.1                                                                         EPB41       184.24
  P11171              2.742    Up               Protein 4.1                                                                         EPB41       63.691
  P11171              0.416    Down             Protein 4.1                                                                         EPB41       125.97
  P11171              0.266    Down             Protein 4.1                                                                         EPB41       54.772
  P67775              0.352    Down             Serine/threonine‐protein phosphatase 2A catalytic subunit alpha isoform             PPP2CA      78.149
  P02042              1.625    Up               Hemoglobin subunit delta                                                            HBD         120.23
  P68036              1.742    Up               Ubiquitin‐conjugating enzyme E2 L3                                                  UBE2L3      90.793
  P16452              1.313    Up               Erythrocyte membrane protein band 4.2                                               EPB42       360.48
  P16452              0.72     Down             Erythrocyte membrane protein band 4.2                                               EPB42       189.43
  P02652              0.223    Down             Apolipoprotein A‐II                                                                 APOA2       89.123
  P02652              0.568    Down             Apolipoprotein A‐II                                                                 APOA2       124.12
  P02765              0.573    Down             Alpha‐2‐HS‐glycoprotein                                                             AHSG        134.99
  P40925              4.17     Up               Malate dehydrogenase, cytoplasmic                                                   MDH1        95.531
  P54727              0.629    Down             UV excision repair protein RAD23 homolog B                                          RAD23B      167.89
  P54252              0.464    Down             Ataxin‐3                                                                            ATXN3       72.315
  P05198              0.564    Down             Eukaryotic translation initiation factor 2 subunit 1                                EIF2S1      103.02
  Q04917              0.154    Down             14--3‐3 protein eta                                                                 YWHAH       54.259
  P00491              1.549    Up               Purine nucleoside phosphorylase                                                     PNP         140.96
  Q13875              2.37     Up               Myelin‐associated oligodendrocyte basic protein                                     MOBP        73.233
  Q13875              2.37     Up               Myelin‐associated oligodendrocyte basic protein                                     MOBP        73.233
  P01857              0.489    Down             Ig gamma‐1 chain C region                                                           IGHG1       156.7
  P27169              0.147    Down             Serum paraoxonase/arylesterase 1                                                    PON1        55.064
  O15554              1.412    Up               Intermediate conductance calcium‐activated potassium channel protein 4              KCNN4       47.039
  P05154              0.405    Down             Plasma serine protease inhibitor                                                    SERPINA5    119.68
  Q5T4S7              0.751    Down             E3 ubiquitin‐protein ligase UBR4                                                    UBR4        98.175
  Q5T4S7              0.263    Down             E3 ubiquitin‐protein ligase UBR4                                                    UBR4        75.764
  P25786              0.528    Down             Proteasome subunit alpha type‐1                                                     PSMA1       169.89
  P49720              0.326    Down             Proteasome subunit beta type‐3                                                      PSMB3       190.26
  Q58WW2              0.464    Down             DDB1‐ and CUL4‐associated factor 6                                                  DCAF6       121.61
  Q58WW2              0.327    Down             DDB1‐ and CUL4‐associated factor 6                                                  DCAF6       147.4
  P02549              1.491    Up               Spectrin alpha chain, erythrocytic 1                                                SPTA1       156.67
  P02549              4.173    Up               Spectrin alpha chain, erythrocytic 1                                                SPTA1       124.08
  P02549              0.779    Down             Spectrin alpha chain, erythrocytic 1                                                SPTA1       155.66
  P02549              0.624    Down             Spectrin alpha chain, erythrocytic 1                                                SPTA1       156.36
  P02549              0.687    Down             Spectrin alpha chain, erythrocytic 1                                                SPTA1       228.19
  P02549              0.301    Down             Spectrin alpha chain, erythrocytic 1                                                SPTA1       158.29
  P61088              2.626    Up               Ubiquitin‐conjugating enzyme E2 N                                                   UBE2N       190.41
  P54725              0.532    Down             UV excision repair protein RAD23 homolog A                                          RAD23A      168.59
  Q00610              0.208    Down             Clathrin heavy chain 1                                                              CLTC        65.231
  P29144              0.572    Down             Tripeptidyl‐peptidase 2                                                             TPP2        104.18
  P51811              0.666    Down             Membrane transport protein XK                                                       XK          138.89
  Q9BSL1              9.707    Up               Ubiquitin‐associated domain‐containing protein 1                                    UBAC1       180.88
  P04075              0.53     Down             Fructose‐bisphosphate aldolase A                                                    ALDOA       139.47
  P02743              0.338    Down             Serum amyloid P‐component                                                           APCS        121.99
  Q16531              10.591   Up               DNA damage‐binding protein 1                                                        DDB1        123.63
  Q5VW32              0.264    Down             BRO1 domain‐containing protein BROX                                                 BROX        57.532
  P30043              0.511    Down             Flavin reductase (NADPH)                                                            BLVRB       187.78
  P62987              0.595    Down             Ubiquitin‐60S ribosomal protein L40                                                 UBA52       136.96
  P45974              0.742    Down             Ubiquitin carboxyl‐terminal hydrolase 5                                             USP5        173.72
  P02655              0.238    Down             Apolipoprotein C‐II                                                                 APOC2       80.585
  O14818              0.484    Down             Proteasome subunit alpha type‐7                                                     PSMA7       56.916
  Q15843              9.91     Up               NEDD8                                                                               NEDD8       206.18
  Q15843              3.159    Up               NEDD8                                                                               NEDD8       207.82
  Q15843              13.049   Up               NEDD8                                                                               NEDD8       84.365
  P13716              0.402    Down             Delta‐aminolevulinic acid dehydratase                                               ALAD        53.453
  Q9NR09              0.242    Down             Baculoviral IAP repeat‐containing protein 6                                         BIRC6       45.357
  P0CG05              0.383    Down             Ig lambda‐2 chain C regions                                                         IGLC2       131.82
  Q96GG9              0.645    Down             DCN1‐like protein 1                                                                 DCUN1D1     120.76
  P55072              0.18     Down             Transitional endoplasmic reticulum ATPase                                           VCP         45.883
  P55072              0.622    Down             Transitional endoplasmic reticulum ATPase                                           VCP         94.114
  P01009              0.13     Down             Alpha‐1‐antitrypsin                                                                 SERPINA1    71.451
  P02679              0.305    Down             Fibrinogen gamma chain                                                              FGG         123.86
  Q93034              2.055    Up               Cullin‐5                                                                            CUL5        211.64
  P07738              0.593    Down             Bisphosphoglycerate mutase                                                          BPGM        134.44
  P23526              13.226   Up               Adenosylhomocysteinase                                                              AHCY        49.188
  P04406              0.66     Down             Glyceraldehyde‐3‐phosphate dehydrogenase                                            GAPDH       92.439
  P27105              0.51     Down             Erythrocyte band 7 integral membrane protein                                        STOM        134.73
  P00915              0.322    Down             Carbonic anhydrase 1                                                                CA1         65.428
  P00915              0.705    Down             Carbonic anhydrase 1                                                                CA1         147.17
  P00915              0.116    Down             Carbonic anhydrase 1                                                                CA1         110.34
  P68371              0.547    Down             Tubulin beta‐4B chain                                                               TUBB4B      167.61
  P28289              0.655    Down             Tropomodulin‐1                                                                      TMOD1       95.822
  P69905              0.717    Down             Hemoglobin subunit alpha                                                            HBA1        199.81
  P69905              3.223    Up               Hemoglobin subunit alpha                                                            HBA1        168.55
  P11277              0.748    Down             Spectrin beta chain, erythrocytic                                                   SPTB        108.63
  P11277              0.47     Down             Spectrin beta chain, erythrocytic                                                   SPTB        142.89
  P11166              0.387    Down             Solute carrier family 2, facilitated glucose transporter member 1                   SLC2A1      136.57
  Q8IZP2              0.627    Down             Putative protein FAM10A4                                                            ST13P4      127.36
  Q99436              0.099    Down             Proteasome subunit beta type‐7                                                      PSMB7       103.88
  Q99436              0.17     Down             Proteasome subunit beta type‐7                                                      PSMB7       103.88

*Gene Ontology of Differentially Quantified Proteins* {#os12556-sec-0020}
-----------------------------------------------------

To investigate the features of the whole blood differentially expressed proteins upon postmenopausal osteoporosis patients and healthy postmenopausal women, classification of GO annotation was performed. GO is an important bioinformatics analysis method and tool for expressing various properties of genes and gene products. It is divided into three broad categories: biological process, cellular component, and molecular function. In quantified proteins with upregulated ubiquitinated sites, cellular process (14%), single‐organism process (14%), biological regulation process (12%), response to stimulus process (12%), and metabolic process (12%) were leading categories when biological processes were evaluated (Fig. [1](#os12556-fig-0001){ref-type="fig"}A); cell (24%) and organelle (22%)‐related proteins stood out in the cellular component analysis (Fig. [1](#os12556-fig-0001){ref-type="fig"}B); molecular function analysis showed that the top two functions were binding (42%) and catalytic activity (23%, Fig. [1](#os12556-fig-0001){ref-type="fig"}C).

![Gene Ontology annotations of quantified proteins with differential sites: (A) biological process annotation of quantified proteins with upregulated ubiquitinated sites; (B) cellular component annotation of quantified proteins with upregulated ubiquitinated sites; (C) molecular function annotation of quantified proteins with upregulated ubiquitinated sites; (D) biological process annotation of quantified proteins with downregulation ubiquitinated sites; (E) cellular component annotation of quantified proteins with downregulation ubiquitinated sites; (F) molecular function annotation of quantified proteins with downregulation ubiquitinated sites; (G) biological process annotation of all quantified proteins; (H) cellular component annotation of all quantified proteins; and (I) molecular function annotation of all quantified proteins.](OS-11-1187-g001){#os12556-fig-0001}

As for quantified proteins with downregulation ubiquitinated sites, cellular process (12%), biological regulation process (11%), single‐organism process (11%), metabolic process (11%), response to stimulus process (10%) and localization process (9%) were important in biological processes (Fig. [1](#os12556-fig-0001){ref-type="fig"}D); cell (22%) and organelle (22%) related proteins still stood in leadership in the cellular component analysis (Fig. [1](#os12556-fig-0001){ref-type="fig"}E); the top two functions of molecular function were binding (47%) and catalytic activity (25%, Fig. [1](#os12556-fig-0001){ref-type="fig"}F).

To explore the cellular functions of differentially regulated proteins in whole blood from healthy postmenopausal women and postmenopausal osteoporosis patients, functional enrichment was conducted in the GO pathway. In the GO functional clustering analysis of upregulated sites with corresponding proteins, ubiquitin conjugating enzyme activity and ubiquitin‐like protein conjugating enzyme activity were equally highly enriched in molecular function, spectrin‐associated cytoskeleton was the most highly enriched in cellular component, and purine‐containing compound catabolic process was the most enriched in biological process (Fig. [2](#os12556-fig-0002){ref-type="fig"}A). However, the threonine‐type peptidase activity and threonine‐type endopeptidase activity were equally highly enriched in molecular function; blood microparticles were the most highly enriched in cellular component; and negative regulation of multicellular organismal process was the most enriched in biological process in the GO functional clustering analysis of downregulated ubiquitinated sites with corresponding protein (Fig. [2](#os12556-fig-0002){ref-type="fig"}B). Simultaneously, in the GO functional clustering analysis of all differentially expressed proteins, structural molecule activity was the most highly enriched in molecular function; extracellular space was the most highly enriched in cellular component, followed by blood microparticles; regulation of cell adhesion was the most highly enriched in biological process (Fig. [2](#os12556-fig-0002){ref-type="fig"}C).

![Gene Ontology enrichment results for upregulated ubiquitinated sites with corresponding proteins (A), downregulated ubiquitinated sites with corresponding proteins (B), and all differentially expressed proteins (C), the horizontal axis value is a negative logarithmic transformation of significant *P* values (*P* \< 0.05).](OS-11-1187-g002){#os12556-fig-0002}

*KEGG Pathway Analysis of Differentially Quantified Proteins* {#os12556-sec-0021}
-------------------------------------------------------------

KEGG is an information network that links known intermolecular interactions (<http://www.kegg.jp/> or <http://www.genome.jp/kegg/>), as well as an encyclopedia of genes and genomes. The KEGG pathway mainly includes: metabolism, genetic information processing, environmental information processing, cellular processes, human diseases, drug development, and the like[39](#os12556-bib-0039){ref-type="ref"}.

The KEGG pathways of quantified proteins with upregulation ubiquitinated sites included glyoxylate and decarboxylate metabolism (Fig. [3](#os12556-fig-0003){ref-type="fig"}A), ubiquitin mediated proteolysis (Fig. [3](#os12556-fig-0003){ref-type="fig"}B), dopaminergic synapse (Fig. [3](#os12556-fig-0003){ref-type="fig"}C), salivary secretion (Fig. [3](#os12556-fig-0003){ref-type="fig"}D) and Parkinson\'s disease (Fig. [3](#os12556-fig-0003){ref-type="fig"}E). However, the KEGG pathways of quantified proteins with downregulation ubiquitinated sites were coagulation and complement cascades (Fig. [4](#os12556-fig-0004){ref-type="fig"}A), nitrogen metabolism (Fig. [4](#os12556-fig-0004){ref-type="fig"}B), hippo signaling pathway (Fig. [4](#os12556-fig-0004){ref-type="fig"}C), and the PPAR signaling pathway (Fig. [4](#os12556-fig-0004){ref-type="fig"}D). The KEGG pathways of all quantified proteins were nucleotide excision repair (Fig. [5](#os12556-fig-0005){ref-type="fig"}A), adrenergic signaling in cardiomyocytes (Fig. [5](#os12556-fig-0005){ref-type="fig"}B), hepatitis C (Fig. [5](#os12556-fig-0005){ref-type="fig"}C), hippo signaling pathway (Fig. [5](#os12556-fig-0005){ref-type="fig"}D), coagulation and complement cascades (Fig. [5](#os12556-fig-0005){ref-type="fig"}E), and oocyte meiosis (Fig. [5](#os12556-fig-0005){ref-type="fig"}F).

![KEGG pathway of quantified proteins with upregulated ubiquitinated sites: (A) glyoxylate and decarboxylate metabolism; (B) ubiquitin mediated proteolysis; (C) dopaminergic synapse; (D) salivary secretion. (E) Parkinson\'s disease (red indicates the level of the protein is upregulated, bright green indicates the level of the protein is downregulated, and yellow indicates the presence of the node).](OS-11-1187-g003){#os12556-fig-0003}

![KEGG pathway of quantified proteins with downregulation ubiquitinated sites: (A) coagulation and complement cascades; (B) nitrogen metabolism (C) hippo signaling pathway (D) and the PPAR signaling pathway (green indicates the level of the protein is downregulated).](OS-11-1187-g004){#os12556-fig-0004}

![KEGG pathway of all quantified proteins: (A) nucleotide excision repair; (B) adrenergic signaling in cardiomyocytes; (C) hepatitis C; (D) hippo signaling pathway; (E) coagulation and complement cascades; and (F) oocyte meiosis (red indicates the level of the protein is upregulated, bright green indicates the level of the protein is downregulated, and yellow indicates the presence of the node).](OS-11-1187-g005){#os12556-fig-0005}

In the KEGG functional clustering analysis, hsa04120 ubiquitin‐mediated proteolysis was the most highly enriched in upregulated sites with corresponding proteins (Fig. [6](#os12556-fig-0006){ref-type="fig"}A), hsa04610 complement and coagulation cascades were the most highly enriched in downregulated ubiquitinated sites with corresponding proteins (Fig. [6](#os12556-fig-0006){ref-type="fig"}B), and hsa04114 oocyte meiosis was the most highly enriched in all differentially expressed proteins (Fig. [6](#os12556-fig-0006){ref-type="fig"}C).

![KEGG enrichment results of all quantified proteins: The horizontal axis value is a negative logarithmic transformation of significant *P*‐values (*P* \< 0.05).](OS-11-1187-g006){#os12556-fig-0006}

Discussion {#os12556-sec-0022}
==========

Quantitative analysis of ubiquitylomes was conducted in this study. The ubiquitylomes analysis of the whole blood in seven healthy postmenopausal women and seven postmenopausal osteoporosis patients demonstrated that 32 sites on 25 proteins were upregulated and 101 sites on 77 proteins were downregulated. However, increasing the number of samples may make the results more credible.

*Gene Ontology Analysis of Differentially Quantified Proteins* {#os12556-sec-0023}
--------------------------------------------------------------

In our study, the GO analysis showed that cellular process, single‐organism process, biological regulation process, response to stimulus process, and metabolic process were leading biological process categories in quantified proteins both with upregulated ubiquitinated sites (Fig. [1](#os12556-fig-0001){ref-type="fig"}A) and downregulation ubiquitinated sites (Fig. [1](#os12556-fig-0001){ref-type="fig"}D). The top two functions of molecular function were binding and catalytic activity in quantified proteins with upregulated ubiquitinated sites (Fig. [1](#os12556-fig-0001){ref-type="fig"}C) and downregulated ubiquitinated sites (Fig. [1](#os12556-fig-0001){ref-type="fig"}F).

In contrast, the GO functional clustering analysis revealed that the enrichment results of the same cellular components, molecular function, and biological process vary widely between downregulated sites with corresponding proteins and upregulated sites with corresponding proteins.

Blood microparticles were the most highly enriched in cellular component of downregulated sites with corresponding proteins, and the second most highly enriched in cellular component of all differentially expressed proteins, it was not enriched in cellular component of upregulated sites with corresponding proteins. Ubiquitin conjugating enzyme activity and ubiquitin‐like protein conjugating enzyme activity were the most highly enriched in molecular function of upregulated sites with corresponding proteins, but they were not enriched in downregulated sites with corresponding proteins.

The above results suggest that there was a huge difference in cell biological activity between quantified proteins with upregulated ubiquitinated sites and downregulated ubiquitinated sites in postmenopausal osteoporosis.

*KEGG Pathway Analysis of Quantified Proteins* {#os12556-sec-0024}
----------------------------------------------

The KEGG pathway analysis of quantified proteins with differentiated ubiquitinated sites revealed 13 kinds of molecular interactions and functional pathways. Among them, glyoxylate and decarboxylate metabolism (Fig. [3](#os12556-fig-0003){ref-type="fig"}A) and dopaminergic synapse (Fig. [3](#os12556-fig-0003){ref-type="fig"}C) have both found in quantified proteins with upregulation ubiquitinated sites and neither found the relationship between them and bone metabolism. On the other hand, ubiquitin‐mediated proteolysis (Fig. [3](#os12556-fig-0003){ref-type="fig"}B), salivary secretion (Fig. [3](#os12556-fig-0003){ref-type="fig"}D), and Parkinson\'s disease (Fig. [3](#os12556-fig-0003){ref-type="fig"}E) were reported all related to bone metabolism. These results reflect those of Fukushima (2017)[40](#os12556-bib-0040){ref-type="ref"}, who found that sustained osteoclast activity is largely due to accumulation of NOTCH2 carrying a truncated C terminus that escapes FBW7‐mediated ubiquitination and degradation. Salivary secretion may contribute to postmenopausal bone health. The most important clinically relevant finding was that MPTP‐induced Parkinsonian features in mice lead to trabecular bone loss through decreased bone formation and increased bone resorption due to changes in the serum circulating factors[41](#os12556-bib-0041){ref-type="ref"}, and Parkinson\'s disease was a risk factor for osteoporosis[42](#os12556-bib-0042){ref-type="ref"}.

Moreover, the hippo signaling pathway (Figs [4](#os12556-fig-0004){ref-type="fig"}C and [5](#os12556-fig-0005){ref-type="fig"}D), coagulation, and complement cascades (Figs [4](#os12556-fig-0004){ref-type="fig"}A and [5](#os12556-fig-0005){ref-type="fig"}E) were enriched both in all quantified proteins and the quantified proteins with downregulated ubiquitinated sites. These results indicated they were in significant position of bone metabolism. This also accords with the KEGG functional clustering analysis in downregulated ubiquitinated sites with corresponding proteins, which showed that hsa04610 complement and coagulation cascades are the most highly enriched (Fig. [6](#os12556-fig-0006){ref-type="fig"}B).

However, the hippo pathway has been considered more important in previous studies of postmenopausal osteoporosis. In multicellular organisms, the hippo pathway is an identified signaling that plays an evolutionarily conserved fundamental role in organ size control, cell proliferation, cell apoptosis and fate determination of stem cells[42](#os12556-bib-0042){ref-type="ref"}, [43](#os12556-bib-0043){ref-type="ref"}, [44](#os12556-bib-0044){ref-type="ref"}. The hippo‐signaling pathway plays an important role in the osteogenic differentiation of mouse bone marrow mesenchymal stem cells[45](#os12556-bib-0045){ref-type="ref"}. Importantly, the hippo‐signaling pathway plays an important role in bone metastasis from breast carcinomar[45](#os12556-bib-0045){ref-type="ref"}.

The other molecular interactions and functional pathways of our study may also be involved in the regulation of bone metabolism in postmenopausal osteoporosis. More research is necessary to understand their roles in postmenopausal osteoporosis. This might help us comprehend the pathogenesis of postmenopausal osteoporosis, and the quantified proteins with differential regulation ubiquitinated sites may be potential diagnostic biomarkers in whole blood.

*Conclusion* {#os12556-sec-0025}
============

The present study expands our understanding of the spectrum of novel targets that are differentially ubiquitinated in whole blood from healthy postmenopausal women and postmenopausal osteoporosis patients. Overall, these findings will contribute toward our understanding of the underlying proteostasis pathways in postmenopausal osteoporosis and the potential identification of diagnostic biomarkers in whole blood.
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###### 

Click here for additional data file.

This work was supported by the National Natural Science Foundation of China (No. 81573754; 81873129) and the "Thirteen Five‐Year" Zhejiang Province Traditional Chinese Medicine (Integrated Chinese and Western Medicine) Key Discipline Construction Plan (No. 2017‐XK‐A16). We thank the staff of the Second Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine for their support throughout these experiments.
